Dr. Philip Dubé is the author of this Drug Discovery World article due to his expertise with animal models and immuno-oncology research:
"Discovering & validating novel therapeutic targets to add to the immuno-oncology arsenal requires refined preclinical models that meet needs for suitability, scalability & clinical relevancy throughout the phases of target discovery & drug validation.
The use of animal models in oncology has undergone a revolution with the advent of cancer immunotherapy, and has become a powerful tool in understanding the fundamental biology of tumour-immune cell interactions and identifying therapeutic targets." Read the complete article at: DDW-Online.com
"Discovering & validating novel therapeutic targets to add to the immuno-oncology arsenal requires refined preclinical models that meet needs for suitability, scalability & clinical relevancy throughout the phases of target discovery & drug validation. The use of animal models in oncology has undergone a revolution with the advent of cancer immunotherapy, and has become a powerful tool in understanding the fundamental biology of tumour-immune cell interactions and identifying therapeutic targets."